VarmX B.V. is manufacturing therapeutic proteins to instantaneously restore blood clotting in bleeding patients.
VarmX has raised €48M across 2 funding rounds from 2 investors, most recently a Series B round in May 2023. Based in Leiden, Netherlands; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors |
|---|
| 2023-05-25 | Series B | €30M | European Innovation Council (EIC),Sound Bioventures | View deal → |
| 2021-10-21 | Other | €18M | European Innovation Council (EIC) | View deal → |
